Incretin mimetic therapy for type 2 diabetes has been on the market for more than 10 years. Find out what you've learned about the GLP-1 agonists, here.
While we wait for results from FDA-mandated CV outcomes studies by SGLT2I makers, there is plenty of (positive) speculation.
What brings patients to your office—and not the specialty office down the street? Insights in this slideshow.
The ADA provides an abridged version for PCPs of its annual Standards of Medical Care. Our slides summarize 6 updates important to primary care.
It's probably too early to pass judgment but data from clinical trials point to decreased bone mineral density and increased treatment-emergent fractures in patients taking the new antidiabetes drugs.
Since June of 2014, the US FDA has approved a number of drugs for a variety of endocrine-related diseases. Here are 10 of them.
SGLT2 inhibitors perform well in older patients and cause minimal hypoglycemia. But caution is advised and here are 5 reasons why.
Endo Tools, Endo Pubs, Glooko--just a few of the mobile apps described here, all designed specifically for the clinical endocrinologist.
Studies looking at add-on treatment with SGLT2 inhibitors show their effects on glycemic control to be roughly additive. Here, a concise look at clinical trial results plus guidance on renal dose adjustment.
All pregnant women should be tested for diabetes by 13 weeks’ gestation and tested again for gestational diabetes between 24 and 28 weeks’ gestation, say new guidelines.